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ABSTRACT 
Carnitine is a vital biologic substance facilitating fatty acids transport into mitochondria for ATP production. 
This study was to investigate the effects of pre-ischemic pharmacological preconditioning (PC) with L-carnitine 
(L-Car) on myocardial infarct size and cardiac functions in ischemic and reperfused isolated rat heart and 
meanwhile on left ventricular glycogen and lactate content. Isolated rat hearts were subjected to 30 min 
coronary artery occlusion followed by 120 min reperfusion. The hearts (n= 8-12) were perfused with L-Car 
(0.5-5 mM) only for 15 min before to 10 min after induction of ischemia. Preconditioning of the hearts with L-
Car provided concentration-dependent cardioprotection as evidenced by improved postischemic ventricular 
functional recovery (developed pressure, left ventricular end diastolic pressure and coronary flow rate) and 
reduced myocardial infarct size (p<0.001). L-Car (2.5 mM) decreased both glycogen (p<0.001) and lactate 
(p<0.05) content in left ventricle during ischemia compared with the control. The results of this study 
demonstrate that L-Car pharmacologically precondition the hearts against ischemic and reperfusion injury in 
part by recovery of postischemic ventricular hemodynamic functions, depletion of glycogen and therefore 
reduction of lactate accumulation.   
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INTRODUCTION 
 
Ischemic preconditioning (IPC) mediated by one or more 
brief periods of ischemia and reperfusion is considered to 
be the most powerful cardioprotective technique of recent 
years (Murry et al., 1996). IPC has two cardioprotective 
phases, early, lasting up to 3-4 h and delayed ischemic 
preconditioning lasting from 1 to 4 days. Attempts to 
increase these phases have met with limited success. 
There is an essential need for developing a 
pharmacological preconditioning approach that can 
significantly increase these phases of cardioprotection.  
Carnitine is an essential cofactor under physiological 
conditions in the intermediary metabolism and transport 
of long-chain fatty acids from the cytoplasm of cells to 
the mitochondrial matrix for ATP production. This 
pathway within the mitochondria is the major source of 
energy for the heart (Neely and Morgan, 1974). Many 
studies have shown that L-carnitine (L-Car) exerts a 
protective effect against ischemic/reperfusion injury, and 
clinical trials confirm these beneficial effects although 
controversial results are observed (Ferrari et al., 2004; 
Arsenian, 1997). Several studies have shown that L-
carnitine reduces ischemic/reperfusion injury in heart by 
counteracting the toxic effect of free fatty acids, which 
increases during ischemia, and by improving glucose 
metabolism (Neely and Morgan, 1974). In addition to 
increase the rate of fatty acid transport into mitochondria, 
L-Car reduces the intramitochondrial ration of Acetyl-
CoA to free CoA, thus stimulating the activity of pyruvate 
dehydrogenase and increasing the oxidation of pyruvate 
(Lopaschuk, 2000). It has also been shown that propionyl-
L-carnitine which penetrates faster than L-Car into 
myocytes is effective in inhibiting of reperfusion 
ventricular fibrillation and production of free radicals 
presumably by accelerating pyruvate dehydrogenase 
pathway (Cui et al., 2003; Lango et al., 2001).  
 
Myocardial glycogen stores are an essential endogenous 
source of ATP formation, enabling the myocytes to 
maintain ion pump activity and cellular integrity during 
no-flow ischemia (Stanley et al., 1992; Eberli et al., 1991; 
Weiss and Hiltbrand, 1985). However, uncontrolled 
glycogenolysis during ischemia may lead to lactate 
accumulation, intracellular acidosis, and cell death (Neely 
and Grotyohann, 1984). Several mechanisms are 
suggested for cardioprotective effects of IPC, including 
preischemic myocardial glycogen depletion (Bradamante 
et al., 2000). The glycogen hypothesis states that 
glycogen depletion occurs during the preconditioning 
episodes and that the resultant lower glycogen levels 
during prolonged ischemia contribute to the attenuation of 
ischemic acidosis. This in turn results in less ischemic 
injury and contributes to improved post ischemic 
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metabolic and contractile recovery. The aim of the present 
study was to study the effects of pre-ischemic 
administration of L-Car on infarct size and postischemic 
cardiac hemodynamic functions. Furthermore, because 
myocardial glycogen content is an important source of 
energy during ischemia (Stanley et al., 1992), we 
investigated the effects of L-Car on left ventricle 
glycogen and lactate content after ischemia.  
 
MATERIALS AND METHODS 
 
Animals 
Male Sprague-Dawley rats (270-330 g) were used in this 
study. Animals were given food and water ad libitum. 
They were housed in the Animal House of Tabriz 
University of Medical Sciences at a controlled ambient 
temperature of 25 ± 2°C with 50 ± 10% relative humidity 
and with a 12-h light/12-h dark cycle (lights on at 7:00 
a.m.). This study was performed in accordance with the 
Guide for the Care and Use of Laboratory Animals 
(National Institutes of Health Publication No 85-23, re-
vised 1985). 
 
Surgical procedure 
Animals were pretreated with i.p. injection of 300 IU 
heparin and anaesthetized by sodium pentobarbital 
(60mg/kg, i.p.). The hearts were excised rapidly and 
mounted on a non-recirculating Langendorff apparatus 
under 100 mmHg pressure at 37.5 °C and perfused with 
modified Krebs–Henseleit (K/H) solution that previously 
equilibrated with 95% O2–5% CO2 (Hausenloy et al., 
2003). A fluid filled latex balloon was introduced into the 
left ventricle through incision in the left atrium and 
inflated to give a pre-load of 8–10 mmHg. A 6/0 braided 
silk suture was placed around the left descending 
coronary artery. Following 20 min stabilization, coronary 
occlusion (30min) was achieved by threading the loose 
ends of the ligature through a polyethylene occluder and 
clamping in place. Release of the clamp allowed 
reperfusion (120 min) of the previously ischemic tissue 
(Hausenloy et al., 2003).  
 
Evaluation of left ventricular function 
Left ventricular functions including left ventricular end 
diastolic pressure (LVEDP) and left ventricular developed 
pressure (LVDP) were measured at regular intervals by a 
pressure transducer connected to the latex balloon 
(Powerlab system, ADInstruments, Australia). Coronary 
flow rate (CFR) was measured by a time collection of the 
coronary perfusate that dripped from the heart.  The heart 
rate (HR) was calculated from the ECG. Rate pressure 
product (RPP) was calculated by multiplying left 
ventricular developed pressure by HR. 
 
Measurement of infarct size 
To determine infarct size, at the end of the 120 min 
reperfusion period, the ligature around the LAD artery 
was re-tied and the heart was slowly perfused with 2-3 ml 
of saline solution containing 0.25% Evans blue dye (w/v) 
via the side arm of the aortic cannula. Perfusion of the 
hearts by Evans blue dye delineates the non-ischemic 
zone of the myocardium as a dark blue area. The hearts 
were freezed at –20°C then the ventricle of the frozen 
hearts were sliced transversely in a plane perpendicular to 
the apico-basal axis into 2 mm-thick sections. The slices 
then incubated by 1% (w/v) triphenyltetrazolium (TTZ) 
solution in phosphate buffer (NaHPO4, 88 mM; NaH2PO4 
1.8 mM, pH= 7.4) for 15 min at 37°C to dye the non-
infracted region (Hausenloy et al., 2003). This procedure 
resulted in the normally perfused tissue being stained 
blue, non-infracted, non-perfused tissue stained brick red 
and infracted tissue remaining unstained and appeared 
pale. TTZ stains the non-infracted myocardium a brick 
red color, indicating the presence of a formazin 
precipitate that results from the reduction of TTZ by 
dehydrogenase enzymes present in viable tissue 
(Zacharowski et al., 2001). The tissue slices were then 
fixed in 10% formalin for 24 hr and then placed between 
two glass cover sheets. The sheets cause that the tissue 
color can clearly be seen also makes a convenient flat 
surface for directly tracing the dimensions of the infarct 
and risk zone on a transparent sheet. The slices were 
drawn onto transparent sheets then by using a 
computerized planimetry package; the percentage of 
infracted tissue within the volume of myocardium at risk 
was calculated (Hausenloy et al., 2003).  
 
Assessment of left ventricular glycogen and lactate 
content 
Total glycogen was measured in triplicate from 
homogenates of frozen biopsies after degradation to 
glucose using the filter-paper technique and spectro-
photometric detection at 340 nm (Solling and Esmann, 
1975; Botker et al., 1995). Lactate was measured from the 
same homogenates using enzymatic analyses and 
spectrophotometric detection as described by Hohorst 
(Hohorst, 1962). 
 
Protocols 
Hearts (n=8-12) were allocated randomly to (a) Drug free 
control; (b) the hearts which were perfused with 0.5, 2.5 
and 5mM of L-Car-enriched K/H solution from 15 min 
before ischemia to 10 min after ischemia. In two other 
groups, one drug free control (Ischemic group) and the 
other treated with 2.5 mM L-Car-enriched Krebs only for 
15 min before ischemia (Pre-ischemic L-Car group), at 
the end of ischemia the hearts were frozen within 2 
second in liquid nitrogen and kept in -80°C until used for 
glycogen and lactate measurement. In this series of 
experiments, two groups of hearts were also used as sham 
operated, non-ischemic groups, the hearts treated exactly 
the same as above without ligation of the coronary artery 
in the presence (Sham+L-Car group) or absence (Sham) 
of L-Car.    
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STATISTICS 
 
Except for glycogen and lactate contents that are 
presented as mean±SD, all results are presented as 
mean±SEM. A one-way ANOVA with LSD post hoc test 
was carried out to test any differences between the mean 
values of different groups. The differences between 
groups were considered significant at a level of p<0.05. 
 
RESULTS 
 
Effects of L-Car on cardiac functions during ischemia 
and reperfusion 
Perfusion of 0.5, 2.5 and 5mM of L-Car-enriched K/H 
solution had no significant effect on LVDP, HR, RPP and 
CFR during ischemia (data was not shown). In all L-Car 
treated groups LVEDP was lower than control value at 
the end of ischemia (pre-reperfusion point; fig.1) which 
attained significance only by 0.5 mM of L-Car (p<0.05). 
Re-opening of the ligated coronary artery in controls 
resulted in an increase in LVEDP in early reperfusion 
time, which continued to 60 min after reperfusion (fig.1). 
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Fig. 1: The effects of pre-ischemic perfusion of isolated 
rat hearts with 0.5-5 mM L-Car on Left Ventricular End 
Diastolic Pressure (LVEDP) in the control and treated 
groups immediately before reperfusion and during 120 
min reperfusion time. **p<0.01, * p<0.05 vs control. Pre-
rep: Pre-reperfusion. Data are expressed as mean ±SEM. 
 
Compared to the control group, pre-ischemic application 
of L-Car by all concentrations lowered the extent of 
LVEDP elevation (fig. 1) and prevented LVDP reduction 
(fig. 2) throughout the reperfusion time. As shown in fig. 
1, LVEDP was significantly (p<0.001; p<0.05) lower than 
control value at 5, 15 and 30 min after reperfusion in the 
L-Car treated groups. Furthermore, compared to pre-
reperfusion point, L-Car (2.5 and 5 mM) reserved RPP 
during the reperfusion period (table 1). Improvement of 
RPP and LVDP by pre-ischemic perfusion of 2.5 and 5 
mM L-Car-enriched K/H solution increased CFR 
throughout the reperfusion phase (table 1). The effect was 
significant during the first 30 min of reperfusion time and 
5 mM of the drug showed greater and longer effect. 
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Fig. 2: The effects of pre-ischemic perfusion of isolated 
rat hearts with 0.5-5 mM L-Car on Left Ventricular 
Developed Pressure (LVDP) in the control and treated 
groups immediately before reperfusion (pre-rep) and 
during 120 min reperfusion time. Data are expressed as 
mean ±SEM. 
 
Effects of L-Car on infarct size  
In control group, the infarct size was 46.3 ± 3.5% while 
pre-ischemic perfusion of 0.5, 2.5, and 5mM of L-Car 
significantly reduced it to 25.9 ± 3, 17.3 ± 1.3 and 20.8 ± 
1.5%, respectively (Fig.3; p<0.001). Risk zone volume 
(area at risk) in all groups was similar and did not show 
significant differences between groups. 
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Fig. 3: The effects of pre-ischemic perfusion of isolated 
rat hearts with 0.5-5 mM L-Car (Carn.) on myocardial 
infarct size as a percentage of risk zone volume. 
**p<0.001 vs. control. Data are expressed as mean ±SEM. 
 
Effects of L-Car on glycogen and lactate content in 
nonischemic and ischemic hearts 
Perfusion of 2.5 mM of L-Car-enriched K/H solution of L-
carntine for 15 min in sham operated, non ischemic 
isolated rat hearts, did not influence left ventricular either 
glycogen or lactate content (fig. 4). Compared to non-
ischemic myocardium (sham group), after 30 min regional 
ischemia (ischemic group), left ventricular glycogen 
content declined slightly but not significantly, while the 
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lactate content increased significantly (p<0.05) by 62% 
(fig. 4). In comparison with the ischemic hearts, pre-
ischemic perfusion of L-Car (2.5 mM; pre-ischemic L-Car 
group) produced a considerable reduction both in 
glycogen (p<0.01) and lactate (p<0.05) content of left 
ventricle (fig. 4).   
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Fig. 4: Left ventricular (LV) glycogen (black columns) 
and lactate (gray columns) content in the hearts perfused 
with krebs in aerobic condition in absence (sham) or 
presence of 2.5 mM L-Car (sham+L-Car); in hearts 
subjected to 30 min regional ischemia without any 
treatment (ischemia) and in hearts that received L-Car 
only for 15 min prior to ischemia (pre-ischemia L-Car). 
*p<0.05; **p<0.01 vs ischemia group; #p<0.01 vs sham. 
Data are expressed as mean ±SD. 
 
DISCUSSION 
 
Several studies have shown that L-carntine reduces 
myocardial ischemia and reperfusion injury by preventing 
the accumulation of free fatty acids and by stimulating the 
activity of pyruvate dehydrogenase and thus improving 
glucose metabolism (Ferrari et al., 2004). We tried three 
different concentrations of L-Car (0.5, 2.5 and 5 mM). 
Pre-ischemic administration of all three concentrations of 
L-Car could precondition the heart as evidenced by its 
ability to lower the infarct size markedly (p<0.001) and 
improved postischemic ventricular functional recovery. 
At the reperfusion phase, pre-ischemic use of L-Car 
reduced LVEDP elevation. Heart rate (HR) and coronary 
flow rate (CFR) did not show significant changes in 
treated groups compared to the control. Rate pressure 
product (RPP) was increased during the reperfusion 
(maybe related to LVDP increase) but it had significant 
value only at 15th min reperfusion time by 2.5 and 5 mM 
of L-Car (Table 1). Improvement of LVDP and RPP at 
reperfusion time and decreasing of LVEDP during 
reperfusion times indicate cardiac functions improvement. 
Among the three different concentratins, 2.5 mM L-Car 
was found to be optimal for preconditioning purpose. It 
was also found in this study that pre-ischemic application 
of L-Car in ischemic/reperfused hearts preconditions the 
hearts by reduction of left ventricular glycogen and lactate 
content.   
 
Glucose catabolism in the heart consists of two distinct 
pathways, glycolysis and mitochondrial glucose 
oxidation. In aerobic condition, the majority of ATP 
produced from glucose catabolism in the heart is normally 
derived from glucose oxidation (Schönekess et al., 1997). 
During ischemia, anaerobic glycolysis from either glucose 
or glycogen results in the production of ATP and as well 
as the intracellular accumulation of lactate and protons 
(H+) as metabolic end products (Heather et al., 1996). 
Glycolytic ATP production can be beneficial during 
myocardial ischemia. In contrast, elevated lactate and H+ 
during ischemia may exacerbate myocardial injury 
(Heather et al., 1996). The effect of high glycogen during 
ischemia may therefore depend on whether the advantage 
of increased glycolytic ATP production outweighs the 
detrimental effect of accumulation of lactate and H+. In 
fact, there are discrepancies on carnitine effect on 
ischemic/reperfusion injury. Diaz et al. (2008) claimed 
that in an anaerobic condition, carnitine administration 
worsens both injury and recovery of contractile functions 
in ischemic/reperfusion rat hearts. However, the 
protective effects of L-carnitine against ischemic/ 
reperfusion injury has been reported in many different 
studies and models (Hosgorler et al., 2010; Guan et al., 
2009; Xie et al., 2006; Onem et al., 2006).    
 
In the present study, left ventricular glycogen store was 
decreased (56%) by pre-ischemic perfusion of L-Car in 
ischemic hearts, and this was associated with significantly 
reduction in lactate content during the subsequent 
ischemic episode. The cardioprotective action of pre-
ischemic used L-Car against ischemic reperfusion injury, 
probably by reduction of glycogen content and therefore, 
of lactate content is consistent with the glycogen 
hypothesis. The glycogen hypothesis states that glycogen 
depletion occurs during the preconditioning episodes and 
that the resultant lower glycogen levels during prolonged 
ischemia contribute to ischemic preconditioning 
(Bradamante et al., 2000; Schaefer, 1995) by reduction of 
lactate and protons production. However, the cardio-
protective effects of L-Car against ischemia/reperfusion 
injury can be related to different mechanisms such as 
stimulating fatty acid oxidation during ischemia, restoring 
the balance between fatty acid and glucose oxidation, 
reducing of toxic effects of long chain free fatty acids 
metabolites, mitigating the noxious effects of oxygen free 
radicals in the reperfused hearts, increasing in coronary 
blood flow and anti-arrhythmic effect (Lango et al., 
2001). Furthermore, some researches suggest that L-Car 
is also crucial in the regulation of carbohydrate 
metabolism in addition to its role in the oxidation of fatty 
acids (Lopaschuk, 2000). Increase in fatty acid oxidation, 
which can be detrimental to cardiac recovery during 
Pharmacological preconditioning with L-carnitine 
Pak. J. Pharm. Sci., Vol.23, No.3, July 2010, pp.250-255 254
reperfusion in ischemic tissue (Lopaschuk, 2000), may 
not ascribe solely the protective efficacy of L-Car. 
Recovery after ischemia has been shown to be improved 
by reducing the availability of fatty acid during 
reperfusion (Lopaschuk et al., 1990). It appears that L-
Car may be beneficial in myocardial ischemia and 
reperfusion by increasing pyruvate dehydrogenase 
activity and shifting cellular energy production from 
oxidation of fatty acids to glycolysis from glycogen and 
therefore by reducing lactate accumulation.  
 
CONCLUSION 
 
The finding of this study indicates that L-Car may act as a 
pharmacological preconditioning agent. Pre-ischemic 
administration of L-Car could precondition the heart as 
evidenced by its ability to lower the infarct size 
profoundly (p<0.001) and to improve postischemic 
functional recovery. The present study also shows that 
pre-ischemic perfusion of isolated rat hearts by 2.5 mM 
L-Car reduces both the myocardial content of glycogen 
and lactate. It can be concluded that L-Car preconditions 
the heart in part by recovery of postischemic ventricular 
hemodynamic functions, depletion of glycogen and 
therefore reduction of lactate accumulation.   
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